Table 2. Adjusted odds ratios for thyroid cancer in diabetes status model.
| Variables | Interpretation | Thyroid cancer case number | OR | 95% CI | P value |
| Basic characteristics | |||||
| Age | Every 1-year increment | 943 | 1.057 | (1.053, 1.062) | <0.0001 |
| Sex | Men vs. Women | 186/757 | 0.424 | (0.358, 0.503) | <0.0001 |
| Diabetes status | Yes vs. No | 149/794 | 0.816 | (0.652, 1.021) | 0.0756 |
| Living region | Northern vs. Taipei | 105/367 | 0.855 | (0.686, 1.066) | 0.1632 |
| Central vs. Taipei | 162/367 | 0.951 | (0.786, 1.150) | 0.6017 | |
| Southern vs. Taipei | 123/367 | 0.991 | (0.800, 1.227) | 0.9324 | |
| Kao-Ping/Eastern vs. Taipei | 186/367 | 1.203 | (1.002, 1.444) | 0.0475 | |
| Occupation* | II vs. I | 197/445 | 1.146 | (0.965, 1.360) | 0.1199 |
| III vs. I | 143/445 | 0.917 | (0.744, 1.131) | 0.4187 | |
| IV vs. I | 158/445 | 0.855 | (0.707, 1.033) | 0.1037 | |
| Potential detection examinations | Yes vs. No | 446/497 | 1.313 | (1.082, 1.594) | 0.0058 |
| Comorbidities | |||||
| Hypertension | Yes vs. No | 181/762 | 0.612 | (0.479, 0.781) | <0.0001 |
| COPD | Yes vs. No | 147/796 | 0.432 | (0.359, 0.520) | <0.0001 |
| Stroke | Yes vs. No | 52/891 | 0.627 | (0.462, 0.851) | 0.0027 |
| Nephropathy | Yes vs. No | 50/893 | 0.619 | (0.460, 0.833) | 0.0015 |
| Ischemic heart disease | Yes vs. No | 81/862 | 0.506 | (0.389, 0.659) | <0.0001 |
| Peripheral arterial disease | Yes vs. No | 34/909 | 0.675 | (0.473, 0.962) | 0.0298 |
| Eye disease | Yes vs. No | 6/937 | 0.406 | (0.174, 0.945) | 0.0366 |
| Obesity | Yes vs. No | 7/936 | 0.577 | (0.273, 1.221) | 0.1504 |
| Dyslipidemia | Yes vs. No | 97/846 | 0.463 | (0.361, 0.593) | <0.0001 |
| Benign thyroid disease | Yes vs. No | 550/393 | 23.094 | (18.868, 28.267) | <0.0001 |
| Other cancer | Yes vs. No | 97/846 | 1.608 | (1.291, 2.002) | <0.0001 |
| Anti-diabetic drugs | |||||
| Sulfonylurea | Yes vs. No | 52/891 | 1.882 | (1.202, 2.947) | 0.0057 |
| Metformin | Yes vs. No | 37/906 | 0.696 | (0.419, 1.155) | 0.1606 |
| Insulin | Yes vs. No | 11/932 | 1.701 | (0.860, 3.364) | 0.1268 |
| Acarbose | Yes vs. No | 4/939 | 0.581 | (0.202, 1.674) | 0.3146 |
| Pioglitazone | Yes vs. No | 1/942 | 0.522 | (0.069, 3.926) | 0.5276 |
| Rosiglitazone | Yes vs. No | 4/939 | 0.669 | (0.230, 1.948) | 0.4613 |
| Other medications | |||||
| Statin | Yes vs. No | 28/915 | 0.552 | (0.360, 0.844) | 0.0061 |
| Fibrate | Yes vs. No | 39/904 | 1.376 | (0.957, 1.976) | 0.0847 |
| ACEI/ARB | Yes vs. No | 115/828 | 0.886 | (0.675, 1.163) | 0.3825 |
| Calcium channel blocker | Yes vs. No | 158/785 | 1.255 | (0.990, 1.592) | 0.0609 |
| Aspirin | Yes vs. No | 138/805 | 0.767 | (0.627, 0.939) | 0.0101 |
| Ticlopidine | Yes vs. No | 7/936 | 1.242 | (0.572, 2.697) | 0.5843 |
| Clopidogrel | Yes vs. No | 1/942 | 0.197 | (0.027, 1.428) | 0.1079 |
| Dipyridamole | Yes vs. No | 122/821 | 0.974 | (0.780, 1.217) | 0.8171 |
| NSAID | Yes vs. No | 827/116 | 0.102 | (0.082, 0.127) | <0.0001 |
*
Categories of occupation are explained in Materials and Methods. OR: odds ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease; ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; NSAID: non-steroidal anti-inflammatory drugs, other than aspirin.